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Aim/Objective/Background Direct-acting oral anticoagulant drugs are marketed worldwide for the primary and secondary
prevention and treatment of thromboembolic disorders. Rivaroxaban, an oral, direct factor Xa inhibitor, is one of the most used.
Rivaroxaban-induced hepatotoxicity is unusual, although a number of adverse reports have recently been reported. Here, we
report two new cases of rivaroxaban-induced hepatitis.
Methods A systematic search of case reports on the MEDLINE database encompassing the years 2008–2016 was carried out.
Additional references were obtained following a manual search of the retrieved papers. We report two new cases of adverse
events occurred in patients treated with rivaroxaban (20mg/die) to prevent systemic embolism, who presented with
hepatocellular liver injury with onset at 8 weeks after initiation of the drug intake.
Results Twenty-six cases were retrieved from MEDLINE (57.7% female, 42.3% male). Using the Roussel Uclaf Causality
Assessment Method (RUCAM) scale, liver injury was classiﬁed as hepatocellular (42.3%), cholestatic (26.9%), or mixed (15.4%).
Older age (≥65 years) was present as a risk factor in 57.7%. The time lapse between initiation of treatment and onset of hepatic
injury ranged from 2 to 180 days (median: 15 days). Our two new patients were diagnosed with drug-induced liver injury
(hepatocellular pattern) using the ‘consensus criteria’, for drug-induced liver injury. Their RUCAM scores were calculated and
assessed as highly probable and probable, respectively. A clinical recovery after rivaroxaban withdrawal was observed.
Conclusion Direct-acting oral anticoagulants have been commonly prescribed, even if safety issues regarding the use of these
drugs are still an ongoing concern, especially in patients experiencing chronic liver disease. Dedicated postauthorization safety
studies should be undertaken to better deﬁne rivaroxaban-induced drug-induced liver injury. Eur J Gastroenterol Hepatol 00:000–000
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Introduction
Direct-acting oral anticoagulants (DOACs) are direct
thrombin and factor Xa (activated factor X) inhibitors.
These drugs, unlike the standard oral vitamin K antago-
nists (e.g. warfarin), are active from the ﬁrst dose and have
predictable pharmacokinetic properties that allow ﬁxed-
dose administration without regular anticoagulant activity
monitoring. However, all currently available DOACs are
associated with a small risk of idiosyncratic hepatotoxicity
[1,2].
The ﬁrst DOAC marketed was ximelagatran, a direct
thrombin inhibitor approved in many countries for pri-
mary deep vein thrombosis (DVT) prophylaxis after
orthopedic surgery [1]. The tolerability of ximelagatran
was initially reported as acceptable in short-term clinical
trials, whereas in longer treatment durations, ~ 8% of
patients experienced elevated liver function values at least
three times over the upper limit of normal, almost all of
these cases occurring within the ﬁrst 6 months of therapy
[3]. Consequently, given the possible risk of hepatotoxi-
city, the drug was withdrawn from the market in 2006 [4].
The more recently developed DOACs have been thor-
oughly investigated in preclinical and clinical trials for the
possibility of hepatic and other toxicities [2].
At present, the DOACs approved for use in the EU, as
well as in other countries, are the direct thrombin inhibitor
dabigatran [5] and the direct factor Xa inhibitors, rivar-
oxaban [6], apixaban [7], and edoxaban [8]. Rivaroxaban
is the ﬁrst oral direct factor Xa inhibitor to have been
marketed worldwide since 2008. It has been approved for
the treatment of DVT, the prevention of recurrent DVT
and pulmonary embolism, the prevention of strokes and
systemic embolism in adults with atrial ﬁbrillation and in
adults undergoing hip/knee replacement surgery, and the
prevention of atherothrombotic events after acute cor-
onary syndrome [6].
With the exception of dabigatran, all DOACs are
metabolized in the liver, and therefore, associated with
liver function alteration. Rivaroxaban is metabolized
by cytochrome P450 (CYP) 3A4, CYP2J2, and CYP-
independent mechanisms, and, further, is a substrate of
P-glycoprotein (P-gp) [1,9]. According to the EU summary
of product characteristics [6], the concomitant use of
rivaroxaban and strong inhibitors of both CYP3A4
and P-gp (such as ketoconazole and itraconazole) is
not recommended. These active substances may increase
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rivaroxaban plasma concentrations to a clinically hazar-
dous degree, which may lead to an increased bleeding risk
[6,9]. Drugs that inhibit only one of these pathways, such
as clarithromycin and erythromycin, are less potent inhi-
bitors and do not appear to have clinically relevant effects.
Potent inducers of CYP3A4, such as rifampicin, may
reduce the effect of rivaroxaban.
Although rivaroxaban-induced hepatoxicity is unusual,
liver injury events had already been reported in premarketing
trials [10]. More recently, a number of case series of patients
treated with rivaroxaban and diagnosed as having drug-
induced liver injury (DILI) have been published [2,10,11].
DILI induced by rivaroxaban is idiosyncratic and covers
a broad spectrum of manifestations, ranging from asymp-
tomatic liver enzyme elevation to severe hepatic failure
requiring liver transplantation [12]. In this context, we report
two more cases of rivaroxaban-induced hepatotoxicity and,
further, we reviewed the currently available literature on
this topic.
Patients and methods
To review the literature regarding rivaroxaban-induced
hepatotoxicity, we carried out a systematic search for all
pertinent reports on the MEDLINE database encompass-
ing the years from 2008 to 2016. Keywords used for liver
damage were as follows: hepatotoxicity, liver injury,
hepatitis, cholestasis, liver failure, liver necrosis, liver
ﬁbrosis, and cirrhosis. Each term was cross-matched with
rivaroxaban. There were no restrictions regarding article
type, patient sex or age, and language of publication.
Additional information was also extracted from the
references of all the retrieved papers.
Currently, we are carrying out a prospective study,
collecting all cases of DILI observed at our Department of
Internal Medicine and Specialties, since January 2000.
Among these, we found two cases showing hepatocellular
liver injury attributable to rivaroxaban exposure. The
causality assessment on these cases was assessed using the
Roussel Uclaf Causality Assessment Method (RUCAM)
[13]. The Naranjo algorithm for causality assessment [14]
was also applied to our cases, although it is not liver
speciﬁc and possibly lacking in speciﬁcity and reproduci-
bility for evaluating drug-associated hepatotoxicity [15].
Results
Twenty-six cases of acute or subacute liver damage fol-
lowing rivaroxaban exposure were retrieved from
MEDLINE search between the years 2008 and 2016
(Table 1) [11,16–22]. Fifteen (57.7%) patients were female
and 11 (42.3%) male. This corresponds to a female/male
ratio of 1 : 36, with an age ranging from 25 to 91 years at
the time of diagnosis (median: 68 years). Age (≥65 years)
was a risk factor present in 15 (57.7%) patients. The time
between initiation of rivaroxaban intake and onset of liver
injury ranged from 2 to 180 days (median: 15 days). The
indications for therapy were typically prevention from
venous thromboembolism in patients undergoing elective
hip or knee replacement surgery and prevention from
stroke and systemic embolism in patients with nonvalvular
atrial ﬁbrillation. Using the RUCAM scale, liver injury was
classiﬁed as hepatocellular (42.3%), cholestatic (26.9%),
or mixed (15.4%). Histological examination, when per-
formed, showed inﬂammatory reactions, necrosis, and
cholestasis (Table 1) [11,16,19].
Serum analysis conﬁrmed a negative viral serology for
active hepatitis B and C in all patients. An autoimmune
reaction was excluded by measuring serum levels of non-
organ-speciﬁc autoantibodies. Alcohol abuse was also
excluded. In some cases, consumption of other medica-
tions was reported. Recovery was generally observed, with
the exception of two patients. One of 11 cases with pre-
dominantly hepatocellular injury (n= 11) resulted in death
[18] from acute liver failure. Among the cholestatic cases
(n=7), one died of paralytic ileus [11]. None of the four
mixed cases died [11,16].
In the following section, we describe the two new cases
observed at our unit over the past year. Using the ‘con-
sensus criteria’ for DILI these patients were diagnosed with
hepatocellular liver injury. The RUCAM scores were cal-
culated as 9 (highly probable) and 8 (probable), respec-
tively. Therefore, rivaroxaban intake was interrupted,
whereas any other medications were continued. A rapid
normalization of aminotransferase values and clinical and
biochemical recovery after rivaroxaban withdrawal were
observed.
Report of new cases
Case 1
A 79-year-old White man with nonvalvular atrial ﬁbrilla-
tion was treated with rivaroxaban (20mg/die) to prevent
systemic embolism. Two months after starting rivarox-
aban treatment, he developed fatigue, jaundice, and itching
and was admitted to our unit of internal medicine. The
patient’s features are reported in Table 2. On admission,
diagnostic tests revealed elevated serum liver enzyme levels
compatible with liver hepatocellular injury: aspartate
aminotransferase (AST) was 33 times above the upper
normal limit (UNL); alanine aminotransferase (ALT) was
35×UNL; total bilirubin was 21.83 mg/dl; alkaline phos-
phatase (AP) was 2×UNL; and γ-glutamyl transpeptidase
(GGT) was 7×UNL. The patient had no history of alcohol
or drug abuse or metabolic disease, such as diabetes. Viral
hepatitis was excluded by serological laboratory tests (IgM
anti-HAV, HBsAg, and IgG anti-HCV); non-organ-speciﬁc
autoantibodies, antinuclear antibody, anti-mitochondrial
antibody, liver-kidney microsomal antibody, were also
negative. Abdominal ultrasound and contrast-enhanced
computed tomography scan did not show liver steatosis,
biliary obstruction, or pancreatic or liver mass; whole-
body PET scan result was negative. Rivaroxaban was
discontinued on the ﬁrst day of hospitalization and low-
molecular-weight heparin was started; other drugs such as
ramipril, bisoprolol, digoxin, and furosemide were con-
tinued because the patient had been following this therapy
for a long time. The RUCAM score was calculated as 9
(rivaroxaban-induced DILI highly probable).
Relevant criteria for this case assessment were a close
and plausible temporal relationship, a known and labeled
adverse drug reaction, and negative differential diagnosis
for any alternative diagnosis. One week after withdrawal
of rivaroxaban treatment, aminotransferases level started
to fall, as did bilirubin; AP was 1.5×UNL and GGT was
7×UNL. At follow-up, 4 weeks after the suspension of
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Table 1. Clinical data of the events associated with rivaroxaban
References Sex Age RVXB indication
RVXB dose/day
(mg) Latency (days) Symptoms Outcome Pattern Liver histology RUCAM
Harder et al. [1] Male 78 Knee replacement 10 14 Painless, jaundice, nausea Death (paralytic ileus) C Cholestasis and portal inﬂammation with eosinophilic
inﬁltration
9
Female 83 Knee replacement 10 16 Painless, jaundice, and nausea Recovery C Centrilobular cholestasis and portal inﬂammation of
mixed cellularity
5
Male 74 Atrial ﬁbrillation 20 <50 Painless and jaundice Recovery H ND 7
Male 63 Atrial ﬁbrillation 20 5 Nausea and vomiting Recovery H ND 3
Female 91 Atrial ﬁbrillation 15 14 Painless, jaundice, and nausea Recovery C ND 9
Female 64 Atrial ﬁbrillation 20 <40 No symptoms Recovery M ND 7
Male 75 Knee replacement 20 15 Painless and jaundice Recovery H ND 9
Female 69 Knee arthroscopy 10 13 Fatigue and loss of appetite Recovery M ND 9
Female 61 Knee surgery 10 20 Jaundice, nausea, and pruritus Recovery H ND 6
Female 60 Knee replacement 10 14 Jaundice, fatigue, and vomiting Recovery ND ND 6
Female 41 Leg surgery 10 20 Jaundice, fatigue, vomiting, and
pruritus
Recovery H ND 7
Female 78 Knee replacement 10 62 Jaundice, nausea, and diarrhea Recovery H ND 5
Male 73 Knee replacement 10 3 Jaundice, nausea, and mild pain Recovery M ND 6
Female 42 Leg surgery 10 29 Jaundice and nausea Recovery H ND 8
Liakoni et al. [2] Male 52 Leg surgery 10 60 Nausea, reduced appetite, and
jaundice
Recovery H Severe lobular hepatitis with perivenular conﬂuent
necrosis
4
Female 73 Knee replacement 10 30 Nausea, jaundice, and pruritus Recovery M ND 7
Lee et al. [3] Female 65 Prevention pulmonary
embolism
30 2 – Recovery ND ND 9
Female 25 Prevention pulmonary
embolism
30 3 Right hypochondrial pain Recovery ND ND 6
Male 69 Treatment of deep vein
thrombosis
30 3 ND Recovery C ND 6
Female 45 Treatment of deep vein
thrombosis
30 3 ND Recovery ND ND 5
Male 54 Prevention pulmonary
embolism
30 3 ND Recovery H ND 5
Keisu et al. [4] Female 89 Atrial ﬁbrillation 20 7 Jaundice and tenderness in
epigastrium
Death (acute liver
failure)
H ND 6
Pradaxa [5] Male 77 Treatment of thrombosis ND 45 Fever, malaise, fatigue, and
arthralgia
Recovery C Conﬂuent area of necrosis containing a neutrophilic
inﬂammatory inﬁltrate
8
Xarelto [6] Female 58 Prevention pulmonary
embolism
30 8 No symptoms Recovery C ND 8
Eliquis [7] Male 67 Atrial ﬁbrillation 20 180 No symptoms Recovery H ND 8
Lixiana [8] Male 71 Atrial Fibrillation 15 30 Jaundice, pruritus, fatigue Recovery C ND 4
This study Male 79 Atrial ﬁbrillation 20 56 Fatigue, jaundice and pruritus Recovery H ND 9
Female 84 Atrial ﬁbrillation 20 49 Fatigue and discomfort Recovery H ND 8
C, cholestatic pattern; H, hepatocellular pattern; M, mixed pattern; ND, no data; RUCAM, Roussel Uclaf Causality Assessment Method; RVXB, rivaroxaban.
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rivaroxaban treatment, serum liver enzymes were within
the normal range and the patient was completely asymp-
tomatic (Fig. 1). Other drugs were therefore classiﬁed as
unlikely alternative causes.
The Naranjo probability scale for causality assessment
[14] score was 7 (probable). The score was derived as
follows: one point for the previous reports of an adverse
reaction in patients treated with rivaroxaban; two points
for the adverse event occurring after drug intake; one point
for improvement in the adverse reaction when rivaroxaban
administration was stopped, one point for the absence of
alternative causes, and two points for conﬁrmation of
diagnosis by objective evidence.
Case 2
The second patient was an 84-year-old White woman,
having nonvalvular atrial ﬁbrillation, treated with rivarox-
aban (20mg/die) to prevent systemic embolism. Seven weeks
after starting rivaroxaban treatment, she developed fatigue
and discomfort and required hospitalization. On admission,
blood tests revealed hepatocellular liver injury: AST/ALT
were 3/9 UNL, GGT was 6×UNL, and AP was within the
normal range. Major hepatotropic virus serology (hepatitis
A virus, hepatitis B virus, and hepatitis C virus) and non-
organ-speciﬁc autoantibodies (antinuclear antibody, anti-
mitochondrial antibody, liver-kidney microsomal antibody)
showed negative results. The patient had no history of
alcohol or drug abuse or metabolic disease, such as diabetes.
Abdominal liver ultrasonography and computed tomo-
graphy scan showed normal ﬁndings with no signs of stea-
tosis, biliary obstruction, or mass. Rivaroxaban intake was
suspected as a potential cause for hepatocellular injury.
Further clues supporting this clinical suspicion were the
previous case report (case 1) and the temporal relationship
(within 7 weeks). Rivaroxaban therapy was discontinued on
the sixth day of hospitalization, and low-molecular-weight
heparin was started, whereas any other drugs (lansoprazole,
amlodipine, carvedilol, or furosemide) were continued. The
RUCAM causality score was calculated as 8 (rivaroxaban-
induced DILI, probable), whereas according to the Naranjo
algorithm, the score was 4 (relationship ‘possible’). Liver
enzyme levels and GGT rapidly normalized after suspension
of rivaroxaban treatment: after one week, aminotransferases
were 1.5×UNL, GGT was 2.5 UNL, and bilirubin within
normal range. The patient was not further exposed to riv-
aroxaban (patient details are reported in Table 2).
Discussion
In the last 10 years, DOACs have been approved for the
primary and secondary prevention and treatment of
thromboembolic disorders. With the exception of dabiga-
tran, DOACs are metabolized by the liver with the invol-
vement of CYP3A4, and associated with liver function
alteration and serum enzyme elevation at an incidence of
between 1/100 and 1/1000 patients [6–8]. DOACs have
been under close surveillance since ximelagatran was ﬁrst
associated with hepatoxicity during the postmarketing
phase, leading to its withdrawal [4]. In fact, the 2013
European guidance for the use of DOACs recommends
yearly monitoring of liver function [23].
A meta-analysis of 29 phase III clinical trials, including
152 116 patients randomized to receive dabigatran, riv-
aroxaban, apixaban, or edoxaban versus conventional
therapy or placebo, found no increased risk of hepato-
toxicity with these drugs [24]. However, according to ‘the
rule of three’ (which states that if a particular event does
not occur in a population of 3000 patients, it can be
concluded, with 95% conﬁdence, that 1/1000 patients will
be affected), the size of clinical trial patient populations is
often too small to determine the risk levels associated with
rare idiosyncratic adverse drug reactions, like DILI. In
addition, clinical trial evaluations are also limited by their
short treatment duration and exclusion of patients with other
potential risk factors (e.g. pre-existing liver disease) [2].
Severe and even fatal cases of acute liver toxicity in
patients treated with rivaroxaban have been reported in
the literature [2,11,16–22]. To date, rivaroxaban-induced
liver injury events have been described in several case
reports: in this study, we reviewed 26 published clinical
reports and have added two new cases in which hepato-
toxicity, assessed by RUCAM as ‘probable’ or ‘highly
probable’, was the main adverse event. Furthermore, in the
case series reviewed, the main features of the liver damage
were the short latency and rapid onset of injury. Severe
hepatotoxicity generally occurred within 15 days after
initiation of rivaroxaban, most cases occurring within
7 days. The reported hepatotoxic reactions showed a clear
temporal relationship between drug intake and the onset
of disease: up to 95% of the patients described in the
reports had been taking the drug for a period between
1 day and 2 months, and this time should be considered
‘suggestive’ in the causality assessment according to
RUCAM. Dechallenge was always positive apart from in
two patients. In particular, the time-to-onset data from the
published case reports suggest that early evaluation of
hepatic enzymes (i.e., within the ﬁrst month) should be
considered, at least in patients on a complex treatment
regimen with comorbidities; subsequently, liver function
can be monitored on a yearly basis [25].
The occurrence of hepatotoxicity and the majority of
fatal reports were signiﬁcantly higher in patients older
than 65 years. Fifteen (57.7%) of the 26 cases reviewed
Table 2. Demographic, clinical, and laboratory features of our cases
with drug-induced liver injury by rivaroxaban
Features Case 1 Case 2
Age (years)/sex 79/M 84/F
Latency (weeks) 8 7
Symptoms Fatigue Fatigue
Jaundice Discomfort
Pruritus
Liver enzyme and AP, ×ULN
ALT >35 >9
AP >2 >1
Viral causes
HAV, HBV, HCV Negative Negative
Non-organ-speciﬁc autoantibodies
ANA, AMA, LKM Negative Negative
Liver US Normal Normal
Recovery after rivaroxaban
discontinuation
Recovery in
4 week
Recovery in 1 week
Causality assessment ‘RUCAM’ score 9 8
Rechallenge No No
ALT, alanine aminotransferase; AMA, anti-mitochondrial antibody; ANA, antinuclear
antibody; AP, alkaline phosphatase; F, female; HAV, HBV, HCV, hepatitis A, B, and
C virus, respectively; LKM, liver-kidney microsomal antibody; M, male; ULN, upper
limit of normal; US, ultarsonography.
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presented age as a possible risk factor, and both of our
cases were older than 65 years. Both hepatocellular and
cholestatic patterns of liver injury have been reported with
rivaroxaban. In the cases reviewed, the liver injury pattern
was predominantly hepatocellular (42.3%); cholestatic and
mixed categories were also well distributed (26.9 and
15.4%). Hepatocellular was the pattern in our two cases.
Recovery was generally observed, apart from in two
patients. One of 11 cases with predominantly hepatocel-
lular injury resulted in death from acute liver failure.
Among the cholestatic cases, one resulted in death but from
paralytic ileus. None of the four mixed cases resulted in
death. Both of our patients had a self-limited, benign course
with rapid recovery after rivaroxaban was withdrawn.
The potential mechanisms of DOAC-associated hepato-
toxicity are yet to be fully determined. Among the reported
cases of hepatotoxicity associated with rivaroxaban (Table 1),
ﬁndings available from four liver specimens were also com-
patible with both immune and nonimmune (or metabolic)
mechanisms [11,16,19]. In two biopsies, the main ﬁndings
were centroacinar cholestasis with bile duct injury and portal
lymphocyte and eosinophil inﬁltrate, consistent with an
allergic reaction [11]. The third biopsy showed focal hepa-
tocyte necrosis and mild portal inﬁltrates with sporadic eosi-
nophils; this patient was diagnosed with DRESS (drug rash
with eosinophilia and systemic symptoms) syndrome, which
is an human leukocyte antigen-associated cellular hypersen-
sitivity reaction [19]. In the last biopsy, the main feature was
the centroacinar necrosis, which may be caused by the
accumulation of toxic metabolites and is consistent with a
metabolic reaction [16]. The centroacinar/perivenular loca-
tion of the hepatic necrosis observed in the specimens, cor-
responding to a higher density of CYP3A4, is consistent with
metabolic toxicity owing to rivaroxaban and/or its metabolite
rather than an immune-mediated mechanism [2,16]. Previous
studies have indicated that rivaroxaban is a shared substrate
of the drug transport proteins MDR1 and BCRP; MDR1
inhibitors and loss-of-function BCRP polymorphisms may
therefore alter rivaroxaban pharmacokinetics, and further
studies should explore the potential role of these factors in
rivaroxaban-induced DILI [23,26–28].
An interesting case report described a patient with
suspected rivaroxaban-associated DILI that rapidly resolved
after discontinuation; apixaban was then safely prescribed
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Fig. 1. Clinical course of patients 1 (a) and 2 (b). Effect of rivaroxaban exposure and dechallenge on hepatocellular enzyme values. ALT, alanine amino-
transferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase.
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as an alternative factor Xa inhibitor. This implies that cross
reactivity may not be present and that the mechanism of
injury is likely unrelated to its mechanism of action as an
anticoagulant [22].
By using, the consensus criteria for DILI [12,13], both
our patients were diagnosed with hepatocellular liver
injury, and the RUCAM score was calculated as 9 (highly
probable) for the ﬁrst patient and 8 (probable) for the
second. Other diseases such as viral and autoimmune
hepatitis, exposure to alcohol or toxins, and diabetes were
excluded. The clinical pattern of liver injury was similar in
the two patients, as was the clinical and biochemical
response after discontinuation of rivaroxaban treatment.
Recently, analyses of large international pharmacov-
igilance databases showed that DOACs are likely associated
with a rare but clinically relevant risk of hepatotoxicity.
Consequently, by the end of 2013, the US Food and Drug
Agency adverse event reporting system database contained
17 097 reports linked to DOACs. After 2 years of post-
marketing surveillance, 146 reports of DILI had been sub-
mitted for rivaroxaban, compared with 222 for dabigatran
and only one for apixaban. Thus, there was a deﬁnite dis-
proportionality signal for rivaroxaban [29]. In February 2016,
the European pharmacovigilance database, EudraVigilance,
had accumulated 793 cases of hepatotoxicity with rivarox-
aban, of which 24 cases were acute hepatitis and four fulmi-
nant hepatitis [20]. Analyzing the data, the reported cases with
rivaroxaban appear to be higher, probably because it is the
DOAC most prescribed in Europe, thus accounting for a
larger number of exposed patients [30]. Regarding the risk of
hepatotoxicity, when DOACs and warfarin are compared, the
latter shows lower liver injury hospitalization rates during a
follow-up of 12 months. However, among DOACs, rivarox-
aban shows the highest risk [0.88, 95% conﬁdence interval
(CI): 0.75–1.03] compared with dabigatran (0.57, 95%
CI: 0.46–0.71) and apixaban (0.70, 95% CI: 0.50–0.97).
Predictors of liver injury hospitalization are the type of
anticoagulant given, previous liver and kidney disease, cancer,
anemia, heart failure, and alcohol abuse [31].
In clinical practice, DILI represents a difﬁcult diagnostic
dilemma, being characterized by a wide range of mani-
festations, which vary from an asymptomatic mild increase
in liver enzyme values to acute liver failure, leading to
transplantation or death. Diagnosis involves excluding
other potential causes of hepatotoxicity, as well as identi-
fying a particular pattern of disease manifestation, with a
temporal relationship between treatment initiation and
discontinuation of the suspected drug [32]. In addition,
lipophilicity and hepatic metabolism are features intrinsic
to rivaroxaban, which incriminate this drug as being
potentially responsible for DILI. Thus, although the actual
pathophysiology is at present unknown, an idiosyncratic
mechanism has been hypothesized as the consequence of
rivaroxaban-induced liver injury, which usually occurs
when the drug is administered at therapeutic doses and is
independent from the drug’s expected pharmacological
properties [2]. In fact, in all the cases reviewed rivarox-
aban was given at therapeutic doses. In addition, in some
of the reports, older-aged patients were taking other
medications that might have contributed to the liver injury
[11,16–18,20].
Conclusion
Rivaroxaban-induced hepatotoxicity is unusual. A poten-
tial signal for severe rivaroxaban-induced liver injury has
not yet been fully characterized, although with the
increasing use of this drug, clinicians should be aware of
the potential risk of DILI. In fact, the intrinsic features of
rivaroxaban suggest that its routine use in patients with
severe liver disease is to be avoided. Moreover, all sus-
pected cases of rivaroxaban-associated hepatotoxicity
should be reported to national pharmacovigilance services
to improve our understanding of this potentially life-
threatening adverse drug reaction. A complete and thor-
ough assessment, fully analyzing the pertinent data of
postauthorization safety studies, should be undertaken,
and an active postmarketing surveillance of this DOAC
should be continued.
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